Outbreak of Escherichia coli O104:H4 haemolytic uraemic syndrome in France: outcome with eculizumab
Open Access
- 28 November 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 29 (3), 565-572
- https://doi.org/10.1093/ndt/gft470
Abstract
An outbreak of haemolytic uraemic syndrome (HUS) due to Shiga toxin-secreting Escherichia coli (STEC) O104:H4 from contaminated fenugreek sprouts occurred in June 2011 near Bordeaux, France. In the context of this outbreak, all patients were treated with the monoclonal anti-C5 antibody, eculizumab. The diagnosis of HUS was made based on haemolytic anaemia, low platelet count and acute kidney injury. Data were obtained from initial gastrointestinal symptoms to the end of follow-up 10 weeks after the start of eculizumab. Among 24 cases of STEC gastroenteritis, HUS developed in nine patients (eight adults and one child), 6 (median; range 3–12) days after digestive symptoms begun. The median (range) highest or lowest biological values were platelet count 26 (range 14–93) G/L; haemoglobin 6.6 (range 5–10.7) g/dL; LDH 1520 (range 510–2568) IU/L; creatinine 152 (range 48–797) µmol/L. All patients had extra-renal complications (liver 9, pancreas 5, brain 3 and heart 3). Two patients were dialysed, and one was ventilated. After failure of plasma exchange to increase platelets in the first three patients, eculizumab was administered in all nine patients, 0–4 days after HUS diagnosis (median 1 day). One patient with very severe neurological HUS received immunoadsorption. Outcome was favourable in all patients, with rapid normalization of haemoglobin, platelets, LDH levels, renal function and neurological improvement. There were no deaths and no serious adverse events related to eculizumab. Early treatment of O104:H4 STEC-HUS by eculizumab was associated with a rapid and efficient recovery. Controlled prospective evaluation of eculizumab in STEC-HUS is warranted.This publication has 41 references indexed in Scilit:
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeThe New England Journal of Medicine, 2013
- Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are neededNephrology Dialysis Transplantation, 2012
- Immunoadsorption in patients with haemolytic uraemic syndromeThe Lancet, 2012
- Genomic epidemiology of the Escherichia coli O104:H4 outbreaks in Europe, 2011Proceedings of the National Academy of Sciences of the United States of America, 2012
- Escherichia coli O104:H4 south-west France, June 2011The Lancet Infectious Diseases, 2011
- Eculizumab in Severe Shiga-Toxin–Associated HUSThe New England Journal of Medicine, 2011
- Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli–induced hemolytic uremic syndromeBlood, 2011
- Alternative Pathway of Complement in Children with Diarrhea-Associated Hemolytic Uremic SyndromeClinical Journal of the American Society of Nephrology, 2009
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injuryCritical Care, 2007
- A Case of Hemolytic Uremic Syndrome Caused by Escherichia coli O104:H4Yonsei Medical Journal, 2006